135 related articles for article (PubMed ID: 27254270)
1. Management of candidemia in patients with Clostridium difficile infection.
Falcone M; Venditti M; Sanguinetti M; Posteraro B
Expert Rev Anti Infect Ther; 2016 Jul; 14(7):679-85. PubMed ID: 27254270
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection.
Russo A; Falcone M; Fantoni M; Murri R; Masucci L; Carfagna P; Ghezzi MC; Posteraro B; Sanguinetti M; Venditti M
Clin Microbiol Infect; 2015 May; 21(5):493.e1-4. PubMed ID: 25698658
[TBL] [Abstract][Full Text] [Related]
3. Updates in the epidemiology and management of candidemia and
Falcone M; Tiseo G; Venditti M; Menichetti F
Expert Rev Anti Infect Ther; 2019 May; 17(5):375-382. PubMed ID: 30982376
[No Abstract] [Full Text] [Related]
4. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.
Vincent C; Miller MA; Edens TJ; Mehrotra S; Dewar K; Manges AR
Microbiome; 2016 Mar; 4():12. PubMed ID: 26975510
[TBL] [Abstract][Full Text] [Related]
5. Breakthroughs in the treatment and prevention of Clostridium difficile infection.
Kociolek LK; Gerding DN
Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):150-60. PubMed ID: 26860266
[TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread?
Polivkova S; Krutova M; Petrlova K; Benes J; Nyc O
Anaerobe; 2016 Aug; 40():35-40. PubMed ID: 27155489
[TBL] [Abstract][Full Text] [Related]
7. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile.
Engevik MA; Engevik KA; Yacyshyn MB; Wang J; Hassett DJ; Darien B; Yacyshyn BR; Worrell RT
Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G497-509. PubMed ID: 25552580
[TBL] [Abstract][Full Text] [Related]
8. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of Clostridium difficile infection in patients with cancer.
Hebbard AI; Slavin MA; Reed C; Teh BW; Thursky KA; Trubiano JA; Worth LJ
Expert Rev Anti Infect Ther; 2016 Nov; 14(11):1077-1085. PubMed ID: 27606976
[TBL] [Abstract][Full Text] [Related]
10. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
Lv Z; Peng G; Liu W; Xu H; Su J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection.
Richardson C; Kim P; Lee C; Bersenas A; Weese JS
Anaerobe; 2015 Jun; 33():105-8. PubMed ID: 25769665
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.
Crowther GS; Chilton CH; Longshaw C; Todhunter SL; Ewin D; Vernon J; Karas A; Wilcox MH
J Antimicrob Chemother; 2016 Apr; 71(4):986-91. PubMed ID: 26755495
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, diagnosis and treatment of Clostridium difficile infection.
Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M
Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319
[TBL] [Abstract][Full Text] [Related]
14. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
Freeman J; Baines SD; Jabes D; Wilcox MH
J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea.
Kim J; Kang JO; Kim H; Seo MR; Choi TY; Pai H; Kuijper EJ; Sanders I; Fawley W
Clin Microbiol Infect; 2013 Jun; 19(6):521-7. PubMed ID: 22712697
[TBL] [Abstract][Full Text] [Related]
17. Management of Clostridium difficile infection: thinking inside and outside the box.
Gerding DN; Johnson S
Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
20. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
